치료용 A형 보툴리눔톡신(보톡스) 시장 규모, 점유율, 동향 분석 : 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Therapeutic Botulinum Toxin Type A Market Summary

The global therapeutic botulinum toxin type A market size was estimated at USD 5.2 billion in 2025 and is projected to reach USD 11.0 billion by 2033, growing at a CAGR of 10.2% from 2026 to 2033. This growth is primarily driven by the rising prevalence of neurological and chronic conditions such as migraine, spasticity, and movement disorders, increasing demand for minimally invasive treatment options, and strong clinical evidence supporting its safety and efficacy.

Additionally, expanding therapeutic indications, growing awareness among patients and healthcare providers, and improved access to treatment through specialty clinics and reimbursement support are further contributing to market expansion. The increasing prevalence of neurological and neuromuscular disorders is a major factor driving the demand in the therapeutic botulinum toxin type A industry. Botulinum toxin injections are widely used to treat conditions involving abnormal muscle activity or nerve signaling. Disorders such as spasticity (upper and lower limbs), chronic migraine, dystonia, blepharospasm, and strabismus are among the most common indications for which botulinum toxin type A is used to reduce muscle overactivity and improve patient function. As the global burden of neurological disorders continues to rise due to aging populations and improved diagnosis rates, the demand for effective symptom-management therapies such as botulinum toxin injections has increased significantly.

Among these conditions, chronic migraine has emerged as one of the major therapeutic applications for botulinum toxin type A, after its use for people suffering from spasticity in upper and lower limbs. Patients suffering from chronic migraine experience frequent headache episodes that can severely impact quality of life and productivity. Therapeutic Botulinum Toxin Type A has emerged as an established, on-label treatment for chronic migraine prevention. Approved by regulatory authorities, it is specifically indicated for adults with chronic migraine and not for episodic migraine. The treatment involves injecting small, controlled doses of the neurotoxin into specific head and neck muscle groups following a standardized injection paradigm. Commercially, Botulinum Toxin Type A is widely recognized through products such as Botox, developed by Allergan (now part of AbbVie). Its on-label use in spasticity and chronic migraine has expanded treatment options and established it as a cornerstone therapy in neurology practice.

Global Therapeutic Botulinum Toxin Type A Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the therapeutic botulinum toxin type A market report based on application, end use, and region:

• Application Outlook (Revenue, USD Million, 2021 - 2033)
• On-label
  • Chronic Migraine
  • Spasticity (Upper Limb / Lower Limb)
  • Dystonia
  • Blepharospasm
  • Strabismus
  • Overactive Bladder
  • Others (hyperhidrosis, sialorrhea)
• Off-label
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Specialty Clinics
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
• Asia Pacific
  • China
  • Japan
  • South Korea
  • Australia
  • India
• Latin America
  • Brazil
  • Mexico
• MEA
  • South Africa
  • Saudi Arabia
  • UAE

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Therapeutic Botulinum Toxin Type A Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Therapeutic Botulinum Toxin Type A Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis

Chapter 4. Therapeutic Botulinum Toxin Type A Market: Application Estimates & Trend Analysis

• 4.1. Therapeutic Botulinum Toxin Type A Market: Application Dashboard
• 4.2. Therapeutic Botulinum Toxin Type A Market: Application Movement Analysis, 2021 to 2033 (USD Million)
• 4.3. Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, By Application, Revenue, 2021 to 2033 (USD Million)
• 4.4. On-label
  • 4.4.1. On-label market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.4.2. Chronic Migraine
    • 4.4.2.1. Chronic Migraine market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.4.3. Spasticity (Upper Limb / Lower Limb)
    • 4.4.3.1. Spasticity (Upper Limb / Lower Limb) market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.4.4. Dystonia
    • 4.4.4.1. Dystonia market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.4.5. Blepharospasm
    • 4.4.5.1. Blepharospasm market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.4.6. Strabismus
    • 4.4.6.1. Strabismus market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.4.7. Overactive Bladder
    • 4.4.7.1. Overactive Bladder market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.4.8. Others (hyperhidrosis, sialorrhea)
    • 4.4.8.1. Others (hyperhidrosis, sialorrhea) market estimates and forecasts for 2021 to 2033 (USD Million)
• 4.5. Off-label
  • 4.5.1. Off-label market estimates and forecasts for 2021 to 2033 (USD Million)

Chapter 5. Therapeutic Botulinum Toxin Type A Market: End Use Estimates & Trend Analysis

• 5.1. Therapeutic Botulinum Toxin Type A Market: End Use Dashboard
• 5.2. Therapeutic Botulinum Toxin Type A Market: End Use Movement Analysis, 2021 to 2033 (USD Million)
• 5.3. Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, By Distribution Channel, Revenue, 2021 to 2033 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals market estimates and forecasts for 2021 to 2033 (USD Million)
• 5.5. Specialty Clinics
  • 5.5.1. Specialty clinics market estimates and forecasts for 2021 to 2033 (USD Million)
• 5.6. Others
  • 5.6.1. Others market estimates and forecasts for 2021 to 2033 (USD Million)

Chapter 6. Therapeutic Botulinum Toxin Type A Market: Regional Estimates & Trend Analysis by Application and End Use

• 6.1. Regional Dashboard
• 6.2. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 6.3. North America
  • 6.3.1. North America Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Key Country Dynamics
    • 6.3.2.2. Competitive Scenario
    • 6.3.2.3. Regulatory Framework
    • 6.3.2.4. Reimbursement scenario
    • 6.3.2.5. U.S. Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Competitive Scenario
    • 6.3.3.3. Regulatory Framework
    • 6.3.3.4. Reimbursement scenario
    • 6.3.3.5. Canada Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.4. Europe
  • 6.3.5. Europe Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.6. UK
    • 6.3.6.1. Key Country Dynamics
    • 6.3.6.2. Competitive Scenario
    • 6.3.6.3. Regulatory Framework
    • 6.3.6.4. Reimbursement scenario
    • 6.3.6.5. UK Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.7. Germany
    • 6.3.7.1. Key Country Dynamics
    • 6.3.7.2. Competitive Scenario
    • 6.3.7.3. Regulatory Framework
    • 6.3.7.4. Reimbursement scenario
    • 6.3.7.5. Germany Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.8. France
    • 6.3.8.1. Key Country Dynamics
    • 6.3.8.2. Competitive Scenario
    • 6.3.8.3. Regulatory Framework
    • 6.3.8.4. Reimbursement scenario
    • 6.3.8.5. France Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.9. Italy
    • 6.3.9.1. Key Country Dynamics
    • 6.3.9.2. Competitive Scenario
    • 6.3.9.3. Regulatory Framework
    • 6.3.9.4. Reimbursement scenario
    • 6.3.9.5. Italy Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.10. Spain
    • 6.3.10.1. Key Country Dynamics
    • 6.3.10.2. Competitive Scenario
    • 6.3.10.3. Regulatory Framework
    • 6.3.10.4. Reimbursement scenario
    • 6.3.10.5. Spain Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Asia Pacific
  • 6.4.1. Asia Pacific Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. Japan
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Competitive Scenario
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement scenario
    • 6.4.2.5. Japan Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. China
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Competitive Scenario
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement scenario
    • 6.4.3.5. China Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. India
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Competitive Scenario
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement scenario
    • 6.4.4.5. India Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.5. South Korea
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Competitive Scenario
    • 6.4.5.3. Regulatory Framework
    • 6.4.5.4. Reimbursement scenario
    • 6.4.5.5. South Korea Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.6. Australia
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Competitive Scenario
    • 6.4.6.3. Regulatory Framework
    • 6.4.6.4. Reimbursement scenario
    • 6.4.6.5. Australia Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Latin America
  • 6.5.1. Latin America Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. Brazil
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement scenario
    • 6.5.2.5. Brazil Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Mexico
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement scenario
    • 6.5.3.5. Mexico Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Middle East & Africa
  • 6.6.1. Middle East & Africa Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. South Africa
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement scenario
    • 6.6.2.5. South Africa Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. Saudi Arabia
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement scenario
    • 6.6.3.5. Saudi Arabia Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.4. UAE
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement scenario
    • 6.6.4.5. UAE Therapeutic Botulinum Toxin Type A Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Vendor Landscape
  • 7.2.1. List of key distributors and channel partners
  • 7.2.2. Key company market share analysis, 2025
  • 7.2.3. AbbVie, Inc.
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Ipsen
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Merz Pharma
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Medytox
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Hugel, Inc.
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. Daewoong Pharmaceutical
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives